SPTX vs MRVI
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SPTX · Seaport Therapeutics$18.05 ▼ 1.47%
MRVI · Maravai LifeSciences$6.98 ▼ 2.92%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SPTX -9.0%
- MRVI +87.1%
Head to head
| Metric | SPTX | MRVI |
|---|---|---|
| Price | $18.05 | $6.98 |
| Change today | ▼ 1.47% | ▼ 2.92% |
| Market cap | $966.23M | $1.04B |
| Return, 3 months | -25.0% | -17.2% |
| Return, year to date | – | +114.8% |
| Return, 1 year | – | +86.1% |
| P/E (TTM) | – | – |
| P/B | 2.4 | 5.3 |
| P/E percentile vs own 5y | 87th | 0th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +10.1% |
| Net profit growth (YoY) | -17.1% | +46.7% |
| Gross margin | – | 39.1% |
| Operating margin | – | -25.6% |
| Net margin | – | -30.8% |
| Return on equity | -34.9% | -29.8% |
| Analyst target vs. price | +107.4% | +41.5% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 39 | 43 |
| 30-day volatility | 62.8% | 80.7% |
| Max drawdown, 1 year | -42.2% | -29.6% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MRVI is the largest of the group by market value.
- SPTX has been the calmest stock over the last 30 days.